JP2005506338A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506338A5
JP2005506338A5 JP2003534394A JP2003534394A JP2005506338A5 JP 2005506338 A5 JP2005506338 A5 JP 2005506338A5 JP 2003534394 A JP2003534394 A JP 2003534394A JP 2003534394 A JP2003534394 A JP 2003534394A JP 2005506338 A5 JP2005506338 A5 JP 2005506338A5
Authority
JP
Japan
Prior art keywords
substituted
heterocycle
alkyl
aryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003534394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/032282 external-priority patent/WO2003031410A1/en
Publication of JP2005506338A publication Critical patent/JP2005506338A/ja
Publication of JP2005506338A5 publication Critical patent/JP2005506338A5/ja
Pending legal-status Critical Current

Links

JP2003534394A 2001-10-09 2002-10-09 メラノコルチンレセプターのリガンドならびに関連の配合物および方法 Pending JP2005506338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32829501P 2001-10-09 2001-10-09
US36674502P 2002-03-22 2002-03-22
PCT/US2002/032282 WO2003031410A1 (en) 2001-10-09 2002-10-09 Ligands of melanocortin receptors and compositions and methods related thereto

Publications (2)

Publication Number Publication Date
JP2005506338A JP2005506338A (ja) 2005-03-03
JP2005506338A5 true JP2005506338A5 (https=) 2006-01-05

Family

ID=26986306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003534394A Pending JP2005506338A (ja) 2001-10-09 2002-10-09 メラノコルチンレセプターのリガンドならびに関連の配合物および方法

Country Status (4)

Country Link
US (1) US20030158209A1 (https=)
EP (1) EP1465867A1 (https=)
JP (1) JP2005506338A (https=)
WO (1) WO2003031410A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003061660A1 (en) * 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
AU2003268493A1 (en) 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
WO2004081643A1 (en) * 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
GB0324236D0 (en) * 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
US20050119252A1 (en) * 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
EP1831194A4 (en) * 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
US8257684B2 (en) 2008-03-26 2012-09-04 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2020013085A (es) 2018-06-05 2021-03-02 Crinetics Pharmaceuticals Inc Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
EP4077307B1 (en) 2019-12-18 2025-03-12 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
WO2021133563A1 (en) 2019-12-23 2021-07-01 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
JP2024510260A (ja) 2021-03-19 2024-03-06 クリネティックス ファーマシューティカルズ,インク. 疾患の治療のためのメラノコルチンサブタイプ-2受容体(mc2r)アンタゴニスト
CN113527220A (zh) * 2021-07-26 2021-10-22 京博农化科技有限公司 一种脱硫丙硫菌唑异构体的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243496A1 (de) * 1992-09-03 1994-03-10 Boehringer Ingelheim Kg Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1995034311A1 (en) * 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
WO1998042656A1 (en) * 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU3768799A (en) * 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
WO2000074679A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
JP2003513645A (ja) * 1999-11-12 2003-04-15 メルク エンド カムパニー インコーポレーテッド メラノコルチン−3レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
US7169777B2 (en) * 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
JP2004532838A (ja) * 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use

Similar Documents

Publication Publication Date Title
JP2005506338A5 (https=)
JP2005523254A5 (https=)
JP2004505947A5 (https=)
JP2009528368A5 (https=)
JP2008540554A5 (https=)
JP2015512860A5 (https=)
JP2009542716A5 (https=)
JP2006528617A5 (https=)
JP2010513523A5 (https=)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2008195730A5 (https=)
JP2004517087A5 (https=)
JP2003520856A5 (https=)
JP2011520906A5 (https=)
JP2011507849A5 (https=)
JP2008508315A5 (https=)
JP2009519243A5 (https=)
JP2009533343A5 (https=)
JP2010510233A5 (https=)
JP2009538897A5 (https=)
JP2010511721A5 (https=)
JP2010501478A5 (https=)
JP2004532240A5 (https=)
JPH11193282A5 (https=)
JP2007520440A5 (https=)